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Background 
Docetaxel is an antineoplastic agent widely used in combination with others
cytotoxic agents in many cancers (breast cancer, non-small cell lung cancer,
prostate cancer, etc.). Today, this costly cytotoxic agent is marketed by several
pharmaceutical companies who suggest discarding any remainder immediately after
use, making it a very costly drug.
Purpose 
The aim of this study was to determine the physical-chemical stability of docetaxel
stock solution after the first sampling in the vial.
Materials and methods 
The study was conducted in accordance with European consensus guidelines for the
practical stability of anticancer drugs (1) and by two societies GERPAC and
SFPC (2). The physical-chemical stability was assessed on 3 different vials of
docetaxel (Taxotere 20 mg/mL). On day 0, 2, 4 and 30 triplicate samples of each vial
of docetaxel were assayed by a high performance liquid chromatography (HPLC)
method with UV detection at 230 nm (method validated following ICH guidelines).
Docetaxel concentration at day 0 was considered to be 100% and if the docetaxel
concentrations in samples were greater than 90% in the following days they were
considered stable. The reference concentration was degraded by 20% by addition of
a quantity of 0.01N NaOH in order to produce and observe primary degradation
products. On each vial and on different days, docetaxel UV absorption spectra
between 200 and 600 nm, pH and colour change were compared by a visual
inspection with reference at T = 0, and finally a turbidimetry method at 350, 410
and 530 nm was used to evaluate the formation of visible and sub-visible particles.
Results 
After 30 days, for each sample, no colour or pH change were observed, all UV
spectra and turbidimetry measures were strictly similar. From day 2 to day 30,
docetaxel concentrations were not significantly different to the day 0 solution and
no degradation products were observed in any samples.
According to these results, no significant drug loss was shown during the study
period.
Conclusions 
At a storage temperature between 20 to 25°C for 30 days, docetaxel solution at 20
mg/mL was seen to be stable. The sterility of the solution was not tested because
the handling environment (Iso 5) was strictly controlled and operator validations are
regularly checked.
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